Page 59 - Read Online

Page 20 of 23 Koukourakis et al. J Cancer Metastasis Treat 2022;8:38 https://dx.doi.org/10.20517/2394-4722.2022.43

randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2021;6:128-38. DOI PubMed
42. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J
Am Coll Surg 2008;206:833-46; discussion 846. DOI PubMed PMC
43. Chapman BC, Gleisner A, Rigg D, et al. Perioperative and survival outcomes following neoadjuvant FOLFIRINOX versus
gemcitabine abraxane in patients with pancreatic adenocarcinoma. JOP 2018;19:75-85. PubMed PMC
44. Janssen QP, Buettner S, Suker M, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a
systematic review and patient-level meta-analysis. J Natl Cancer Inst 2019;111:782-94. DOI PubMed PMC
45. Yoo C, Kang J, Kim KP, et al. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic
adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. Oncotarget 2017;8:46337-47. DOI PubMed PMC
46. Ghaneh P, Palmer DH, Cicconi S, et al. ESPAC-5F: four-arm, prospective, multicenter, international randomized phase II trial of
immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy
(CRT) in patients with borderline resectable pancreatic cancer. JCO 2020;38:4505-4505.
47. Yamaguchi J, Yokoyama Y, Fujii T, et al. Results of a phase II study on the use of neoadjuvant chemotherapy (FOLFIRINOX or
GEM/nab-PTX) for borderline-resectable pancreatic cancer (NUPAT-01). Ann Surg 2022;275:1043-9. DOI PubMed
48. Reni M, Zanon S, Balzano G, et al. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and
cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. Eur J Cancer 2018;102:95-102. DOI PubMed
49. Lee JL, Kim SC, Kim JH, et al. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination
chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery 2012;152:851-62. DOI
PubMed
50. Saito K, Isayama H, Sakamoto Y, et al. A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy
for patients with borderline resectable and locally advanced pancreatic cancer. Med Oncol 2018;35:100. DOI PubMed
51. Tajima H, Ohta T, Kitagawa H, et al. Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable
pancreatic cancer. Exp Ther Med 2012;3:787-92. DOI PubMed PMC
52. Heinrich S, Schäfer M, Weber A, et al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic
cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg 2008;248:1014-22. DOI PubMed
53. OʼReilly EM, Perelshteyn A, Jarnagin WR, et al. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and
oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg 2014;260:142-8. DOI PubMed PMC
54. Motoi F, Ishida K, Fujishima F, et al. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic
ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol 2013;20:3794-801. DOI
PubMed
55. Motoi F, Kosuge T, Ueno H, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus
upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol 2019;49:190-4. DOI PubMed
56. Al-batran S, Reichart A, Bankstahl US, et al. Randomized multicenter phase II/III study with adjuvant gemcitabine versus
neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: the NEPAFOX trial. JCO 2021;39:406-406.
57. Sohal D, Duong MT, Ahmad SA, et al. SWOG S1505: results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus
gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA). JCO 2020;38:4504-4504.
58. Ahmad SA, Duong M, Sohal DPS, et al. Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX
versus gemcitabine/nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma. Ann Surg
2020;272:481-6. DOI PubMed PMC
59. Ettrich TJ, Uhl W, Kornmann M, et al. Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer:
updated final results of the randomized phase II AIO-NEONAX trial. JCO 2022;40:4133-4133. DOI PubMed PMC
60. Schwarz L, Bachet J, Meurisse A, et al. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy: a
multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study). JCO 2022;40:4134-4134. DOI
61. Loehrer PJ Sr, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced
pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 2011;29:4105-12. DOI PubMed PMC
62. Hammel P, Huguet F, van Laethem JL, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally
advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial.
JAMA 2016;315:1844-53. DOI PubMed
63. Seshacharyulu P, Baine MJ, Souchek JJ, et al. Biological determinants of radioresistance and their remediation in pancreatic cancer.
Biochim Biophys Acta Rev Cancer 2017;1868:69-92. DOI PubMed PMC
64. Zeng S, Pöttler M, Lan B, Grützmann R, Pilarsky C, Yang H. Chemoresistance in pancreatic cancer. Int J Mol Sci 2019;20:4504.
DOI PubMed PMC
65. Krishnan S, Chadha AS, Suh Y, et al. Focal radiation therapy dose escalation improves overall survival in locally advanced
pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation. Int J Radiat Oncol Biol Phys
2016;94:755-65. DOI PubMed PMC
66. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in
patients with pancreatic cancer. J Clin Oncol 2009;27:1806-13. DOI PubMed PMC
67. Loeffler JS, Durante M. Charged particle therapy-optimization, challenges and future directions. Nat Rev Clin Oncol 2013;10:411-24.
DOI PubMed